The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2018 | CAR T-cell update: what’s new in DLBCL and MM?
CAR T-cells represent an exciting new treatment frontier across a variety of blood cancers. We interviewed David Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center, Seattle, WA, at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, about the newest CAR T-cell therapies on the market. In diffuse large B-cell lymphoma (DLBCL), he highlights axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel, the latter of which has extremely promising safety results, with low levels of cytokine release syndrome and neurotoxicity. Dr Maloney also discusses new multiple myeloma (MM) CAR T-cell treatments, pointing out a trial (NCT02658929) showing deep responses and remission in relapsed patients with multiple prior therapies when treated with the CAR T-cell agent idecabtagene vicleucel (formerly bb2121).
